Xenon Pharmaceuticals (XENE) Net Income towards Common Stockholders (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$102.3 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$102.3 million, down 57.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.3 million (up 86.24% YoY), and the FY2025 annual result was $2.0 million, up 100.84% from the prior year.
• Net Income towards Common Stockholders eased to -$102.3 million in Q1 2026 per XENE's latest filing, from $242.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $242.6 million in Q4 2025 and troughed at -$102.3 million in Q1 2026.
• A 5-year average of -$38.1 million and a median of -$47.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders plunged 146.3% in 2022, then jumped 443.27% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$37.4 million in 2022, then retreated by 19.7% to -$44.7 million in 2023, then plunged by 57.96% to -$70.7 million in 2024, then jumped by 443.27% to $242.6 million in 2025, then slumped by 142.17% to -$102.3 million in 2026.
• Business Quant data shows XENE's Net Income towards Common Stockholders at -$102.3 million in Q1 2026, $242.6 million in Q4 2025, and -$90.9 million in Q3 2025.